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Summary
Leptin regulates energy balance and body weight by activating its receptor LEPRb and multiple downstream signaling
pathways, including the STAT3 and the IRS2/PI 3-kinase pathways, in the hypothalamus. Leptin stimulates activation of
LEPRb-associated JAK2, which initiates cell signaling. Here we identified SH2-B, a JAK2-interacting protein, as a key
regulator of leptin sensitivity, energy balance, and body weight. SH2-B homozygous null mice were severely hyperphagic
and obese and developed a metabolic syndrome characterized by hyperleptinemia, hyperinsulinemia, hyperlipidemia, he-
patic steatosis, and hyperglycemia. The expression of hypothalamic orexigenic NPY and AgRP was increased in
SH2-B−/− mice. Leptin-stimulated activation of hypothalamic JAK2 and phosphorylation of hypothalamic STAT3 and IRS2
were significantly impaired in SH2-B−/− mice. Moreover, overexpression of SH2-B counteracted PTP1B-mediated inhibition
of leptin signaling in cultured cells. Our data suggest that SH2-B is an endogenous enhancer of leptin sensitivity and
required for maintaining normal energy metabolism and body weight in mice.Introduction
Body weight is determined by a balance between energy intake
and energy expenditure. When energy intake exceeds energy
expenditure, excessive energy is stored as triglyceride in adi-
pose tissue, leading to overweight and obesity. The hypothala-
mus is a key area in the central nervous system (CNS) that
controls body weight and energy homeostasis by integrating
various neuronal, hormonal, and nutrient-related signals (Fried-
man and Halaas, 1998; Schwartz and Porte, 2005; Seeley et
al., 2004). Leptin is the primary adipose-derived hormone that
conveys peripheral signals of nutrient storage and availability
to the hypothalamus. Genetic deficiency of either leptin or its
receptor results in severe hyperphagia and morbid obesity
(Chen et al., 1996; Clement et al., 1998; Lee et al., 1996; Mon-
tague et al., 1997; Tartaglia et al., 1995; Zhang et al., 1994).
Obesity is associated with a metabolic syndrome characterized
by hyperlipidemia, hepatic steatosis, and type 2 diabetes.
Leptin receptor mRNA can be alternatively spliced to pro-
duce five different isoforms (LEPRa-e), which have the same
extracellular domain but distinct cytoplastic domains of various
lengths (Lee et al., 1996). LEPRb is the longest isoform and the
only form that mediates cell signaling. LEPRb interacts with
JAK2, a member of the JAK family of cytoplasmic tyrosine ki-
nases. Leptin stimulates activation of JAK2, which initiates var-
ious downstream pathways, including the STAT3 and the IRS2/
phosphatidylinositol (PI) 3-kinase pathways (Carvalheira et al.,
2003; Duan et al., 2004a; Kellerer et al., 1997; Kim et al., 2000;
Vaisse et al., 1996). Disruption of the STAT3 pathway causes
leptin resistance and morbid obesity in mice (Bates et al., 2003;
Cui et al., 2004; Gao et al., 2004). Similarly, inhibition of the
IRS2/PI 3-kinase pathway also induces leptin resistance and
obesity (Lin et al., 2004; Niswender et al., 2001; Suzuki et al.,
2004; Zhao et al., 2002). These observations suggest that bothCELL METABOLISM : AUGUST 2005 · VOL. 2 · COPYRIGHT © 2005 ELSthe STAT3 and the IRS2/PI 3-kinase pathways are required for
leptin regulation of energy homeostasis.
SH2-B is a ubiquitously expressed cytoplasmic protein that
contains a pleckstrin homology (PH) and a Src-homology-2
(SH2) domain and multiple phosphorylation sites (Rui et al.,
1997). In cultured cells, SH2-B binds to JAK2 via its SH2 do-
main, resulting in potentiation of JAK2 activation in response
to growth hormone (Rui and Carter-Su, 1999). SH2-B also
binds via its SH2 domain to multiple receptor tyrosine kinases
including receptors for insulin, insulin-like growth factor-1,
platelet-derived growth factor, fibroblast growth factor, and
nerve growth factor (NGF) (Kong et al., 2002; Kotani et al.,
1998; Qian et al., 1998; Riedel et al., 1997; Rui and Carter-Su,
1998; Rui et al., 1997, 1999). Our recent studies demonstrate
that SH2-B binds simultaneously to both JAK2 and IRS2, pro-
moting leptin-stimulated activation of the PI 3-kinase pathway in
cultured cells (Duan et al., 2004a). To investigate the physiological
role of SH2-B, we and another group have independently gener-
ated SH2-B-deficient mice by homologous recombination (Duan
et al., 2004b; Ohtsuka et al., 2002). We previously reported that
SH2-B deficient mice develop insulin resistance and type 2 di-
abetes (Duan et al., 2004b). Ohtsuka et al. reported an essen-
tial role of SH2-B in reproduction (Ohtsuka et al., 2002).
Because SH2-B enhances JAK2 activation in cultured cells
and JAK2 activation is a rate-limiting step in leptin signaling,
SH2-B may regulate energy homeostasis by modulating leptin
sensitivity in animals. In this work, we demonstrated that genetic
deletion of the SH2-B gene resulted in severe leptin resistance,
hyperphagia, and obesity. Deletion of SH2-B significantly im-
paired leptin-stimulated activation of JAK2 and JAK2-mediated
signaling pathways in the hypothalamus. Thus, SH2-B is a key
cytoplasmic signaling molecule that positively regulates leptin
sensitivity in hypothalamic neurons.EVIER INC. DOI 10.1016/j.cmet.2005.07.004 95
A R T I C L EResults
SH2-B−/− mice develop obesity and metabolic syndrome
SH2-B binds to and activates JAK2 when overexpressed in
cultured cells (Rui and Carter-Su, 1999; Rui et al., 1997). JAK2
mediates cell signaling in response to a variety of hormones
and cytokines including leptin, growth hormone, prolactin, and
erythropoitin. To determine whether SH2-B is involved in leptin
regulation of body weight, SH2-B−/− mice were generated by
homologous recombination as we previously described (Duan
et al., 2004b). Mice were fed normal mouse chow, and postna-
tal growth was monitored over a period of 27 weeks. Both male
and female SH2-B−/− mice in both 129Sv/C57BL/6 mixed and
C57BL/6 genetic backgrounds were markedly obese (Figures
1A–1B). SH2-B−/− homozygotes (all mice used in the following
experiments were in 129Sv/C57BL/6 mixed genetic back-
ground) were born slightly smaller and gained less body weight
during the first 5 weeks of postnatal growth. They then gained
body weight rapidly and exceeded wild-type littermates (Figure
1B). SH2-B−/− males (21 weeks) were approximately two times
heavier than wild-type littermates (wt: 28.4 ± 1.1 g, n = 8; KO:
55.9 ± 1.2 g, n = 7). Similarly, SH2-B−/− females (25 weeks)
were more than 1.7 times heavier than wild-type littermates
(wt: 27.3 ± 1.6 g, n = 8; KO: 47.6 ± 3.1 g, n = 7).
Interestingly, body length (nose to anus) was similar betweenFigure 1. Disruption of the SH2-B gene results in obesity
A) Representative female SH2-B−/− and wild-type littermate (3 months) in both 129Sv/C57BL/6 mixed and C57BL/6 genetic backgrounds.
B) Growth curves of both male (wt: n = 8; KO: n = 10) and female mice (wt: n = 8; KO: n = 8).
C) The mass of epididymal (Epi), inguinal (Ing), and perirenal (Per) fat depots of males (24 weeks; wt: n = 6; KO: n = 8) and females (24 weeks; wt: n = 8; KO: n = 8).
D) Whole-body fat content in male mice (18–19 weeks; wt: n = 8; KO: n = 7).
E) Hematoxylin and eosin staining of inguinal fat from female mice (3 months). *p < 0.05; **p < 0.01.96SH2-B−/− mice and wild-type littermates (17–19 weeks; wt
males: 9.30 ± 0.08 cm, n = 10; KO males: 9.37 ± 0.16 cm, n =
7), suggesting that SH2-B is not required for growth-hormone-
mediated linear growth. To determine whether the excessive
body weight is caused by an increase in adiposity in SH2-B−/−
mice, the mass of individual fat depots and total fat content
were measured. Inguinal fat mass was increased by 4.4- and
5.1-fold in SH2-B−/− females and males, respectively (Figure
1C). Epididymal and perirenal fat masses were increased by
2.7-fold and 2.9-fold in SH2-B−/− mice, respectively (Figure
1C). Whole-body fat content, as measured by dual energy
X-ray absorptiometry, was increased by more than 2.8-fold in
SH2-B−/− males at 18–19 weeks of age (Figure 1D). Moreover,
increased adiposity was primarily caused by adipose hypertro-
phy, with an increase of average adipose diameter by more
than four times in female inguinal fat depots (Figure 1E). SH2-
B−/+ heterozygous mice were relatively normal in body weight
when fed standard mouse chow but developed obesity when
fed a high-fat diet (data not shown).
Obesity is commonly associated with hyperlipidemia and
type 2 diabetes. To determine whether deletion of SH2-B im-
pairs lipid metabolism, we measured free fatty acids (FAA) and
triglyceride (TG) levels in multiple tissues. Plasma FAA in-
creased by 1.8-fold in male and 1.7-fold in female SH2-B−/−
mice, while plasma TG content was elevated by 2.2-fold inCELL METABOLISM : AUGUST 2005
SH2-B regulation of body weightFigure 2. SH2-B−/− mice develop a metabolic syndrome
A) Levels of plasma-free fatty acids (FFA) and triglycerides (TG) in randomly fed male (18 weeks; KO: n = 7; wt: n = 8) and female mice (24 weeks; wt: n = 8; KO: n = 8).
B) (Left panel) Liver weight of male mice (24 weeks; wt: n = 8; KO: n = 6). (Right panel) Representative hematoxylin and eosin staining of hepatic sections from female
mice (24 weeks).
C) TG content in skeletal muscle of male (24 weeks; wt: n = 8; KO: n = 8) and female mice (24 weeks; wt: n = 8; KO: n = 7). TG content was normalized to muscle weight.
D) Total carcass TG content.
E) Fasted and randomly fed blood glucose and insulin in male mice (19–20 weeks; wt: n = 10; KO: n = 8). *p < 0.05; **p < 0.01.male and 1.5-fold in female SH2-B−/− mice (Figure 2A). Liver
mass was increased by 2.3 times in SH2-B−/− mice owing to a
massive accumulation of lipids (hepatic steatosis) (Figure 2B).
TG content in skeletal muscle was also significantly elevated
by 2.2-fold in male and 1.7-fold in female SH2-B−/− mice (Fig-
ure 2C). Consistent with obesity and hyperlipidemia, carcass
analysis revealed that total body TG content was increased by
w2.7 andw2.8 times for SH2-B−/− males and females, respec-
tively (Figure 2D).
To determine whether deletion of SH2-B impairs glucose
metabolism, the levels of plasma insulin and glucose were
measured. SH2-B−/− mice have severe hyperglycemia and hy-
perinsulinemia (Figure 2E). SH2-B−/− males progressively de-
veloped severe glucose intolerance, insulin resistance, and
type 2 diabetes (data not shown), consistent with our previous
report (Duan et al., 2004b).
Deletion of the SH2-B gene results in energy imbalance
Body weight is controlled by a balance between energy intake
and expenditure. Leptin decreases energy intake and increases
energy expenditure, thus promoting weight loss. To determine
whether SH2-B−/− mice are hyperphagic, food intake was mon-
itored over a period of 24 weeks in individually housed mice.
SH2-B−/− males consumed significantly more food than wild-
type littermates after 7 weeks of age (Figure 3A). Energy intake
increased more than 1.8 times in SH2-B−/− males compared to
wild-type littermates at 13 weeks of age. SH2-B−/− females
were also extremely hyperphagic (data not shown). Interest-CELL METABOLISM : AUGUST 2005ingly, the onset of hyperphagia was correlated with the onset
of obesity, suggesting that elevated energy intake may be a
primary cause of obesity in SH2-B−/− mice (Figures 1B and 3A).
To determine whether SH2-B is involved in regulation of en-
ergy expenditure, O2 consumption and CO2/heat production
were measured by indirect calorimetry in SH2-B−/− and wild-
type littermates (17–19 weeks). Surprisingly, SH2-B−/− males
consumed much more O2 and generated more CO2 and heat
during both dark and light phases (Figures 3B–3D). O2 con-
sumption and CO2 production were increased by 58% and
60% in the light phase, and 36% and 32% in the dark phase
in SH2-B−/− males (Figure 3E). Heat production was increased
by 50% in the light phase and 48% in the dark phase in SH2-
B−/− males (Figure 3E). When energy balance was evaluated by
subtracting caloric expenditure as heat (wt: 7.60 ± 0.04 kcal/
mouse/day, n = 8; KO: 11.20 ± 0.06 kcal/mouse/day, n = 8)
from total caloric intake (wt: 16.80 ± 1.70 kcal/mouse/day, n =
8; KO: 26.20 ± 6.30 kcal/mouse/day, n = 8), SH2-B−/− male
mice had a positive energy imbalance 63% higher than wild-
type control mice at 18–19 weeks of age. SH2-B−/− females
also consumed significantly more O2 and generated more CO2
and heat (data not shown). These results demonstrate that the
energy expenditure is significantly higher in SH2-B−/− mice
than wild-type littermates; however, SH2-B−/− mice remain in a
state of positive energy imbalance and become obese, primar-
ily due to extreme hyperphagia.
To verify elevated energy expenditure in SH2-B−/− mice, both
SH2-B−/− males and wild-type littermates were housed individ-97
A R T I C L EFigure 3. Disruption of the SH2-B gene results in energy imbalance
A) Average food intake (kcal/mouse/day) in male mice (wt: n = 8; KO: n = 8). Mice were housed individually, and food intake was monitored over a period of 24 weeks.
B–D) O2 consumption (B) and the production of CO2 (C) and heat (D) in randomly fed male mice (17–19 weeks; wt: n = 8; KO: n = 7). The values were normalized to
lean body mass.
E) Average values from (B)–(D).
F) Body weight in pair-fed male mice (wt: n = 7; KO: n = 7). Mice were housed individually. Each mouse was fed daily (9:00 a.m.) with the same amount of normal
mouse chow. *p < 0.05; **p < 0.01.ually and pair fed for 15 weeks. Under this paradigm, SH2-
B−/− mice gained significantly less body weight than wild-type
littermates (Figure 3F). The reduction of weight gain is most
likely caused by elevated energy expenditure in SH2-B−/− mice.
These data raise a possibility that energy intake and expendi-
ture may be controlled by two distinct neuronal pathways that
may be differentially regulated by SH2-B.
SH2-B−/− mice develop severe leptin resistance
Leptin resistance is a primary risk factor for obesity. To deter-
mine whether deletion of SH2-B leads to leptin resistance,
plasma leptin levels were measured in SH2-B−/− mice. Both
male and female SH2-B−/− mice developed severe hyperlepti-
nemia, a hallmark of leptin resistance. Fasted and randomly
fed plasma leptin levels were 3.2 times and 5.1 times higher in
SH2-B−/− males than wild-type littermates at 15 weeks of age
(7–8 weeks after the onset of hyperphagia and obesity), re-
spectively (Figure 4A). Similarly, randomly fed plasma leptin
levels were 6.4 times higher in SH2-B−/− females than wild-
type littermates at 26 weeks of age (Figure 4A). To determine
whether leptin resistance precedes the onset of obesity, body
composition and plasma leptin were measured in young SH2-
B−/− mice (6–7 weeks) prior to the onset of obesity. Although
total fat content was similar between SH2-B−/− and wild-type
littermates, plasma leptin levels were elevated by 67% in SH2-
B−/− mice (Figure 4B). These data suggest that leptin resistance98(2 mg/kg body weight) or PBS (as control) was injected intra-
Figure 4. Disruption of the SH2-B gene induces hyperleptinemia
A) Plasma leptin levels in male (15 weeks; wt: n = 8; KO: n = 7) and female mice
(26 weeks; wt: n = 8; KO: n = 7).
B) Fat content and randomly fed plasma leptin in young male mice (6–7 weeks;
wt: n = 9; KO: n = 8). *p < 0.05; **p < 0.01.may be a cause, rather than a consequence, of obesity in SH2-
B−/− mice.
To determine whether deletion of SH2-B impairs the ability
of leptin to reduce food intake and weight gain, mouse leptinCELL METABOLISM : AUGUST 2005
SH2-B regulation of body weightperitoneally into SH2-B−/− mice at 7 weeks of age, and food
intake and body weight were monitored. Leptin significantly re-
duced both food intake and weight gain in wild-type animals
compared with PBS. In contrast, leptin was unable to reduce
either food intake or weight gain in SH2-B−/− mice (Figure 5).
Together, these results demonstrate that deletion of SH2-B
causes severe leptin resistance, which may contribute to obe-
sity in SH2-B−/− mice.
Disruption of the SH2-B gene alters hypothalamic
neuropeptide expression
The arcuate nucleus (ARC) in the hypothalamus contains two
distinct populations of leptin-responsive neurons, which coex-
press either orexigenic neuropeptide Y (NPY) and agouti-
related protein (AgRP) or anorexigenic proopriomelanocortin
(POMC) and cocaine- and amphetamine-regulated transcript
(CART) neuropeptides. NPY and AgRP promote energy intake,
whereas α-melanocyte-stimulating hormone (αMSH), a proteo-
lytic product of POMC, decreases energy intake and body
weight (Friedman and Halaas, 1998; Schwartz and Porte, 2005;
Seeley et al., 2004). Leptin decreases the expression of orexi-
genic NPY and AgRP and increases the expression of anorexi-
genic POMC (Elias et al., 1998; Flier, 2004; Kristensen et al.,
1998; Schwartz et al., 1996; Schwartz et al., 1997). NPY, AgRP,
and αMSH may act downstream of leptin receptor to mediate
leptin regulation of feeding and body weight. To determine
whether these neuropeptides are involved in the development
of hyperphagia and obesity in SH2-B−/− mice, the expression
of hypothalamic POMC, NPY, and AgRP was measured in mice
fasted for 8 hr (from 9:00 a.m. to 5:00 p.m.). Total hypothalamic
RNA was extracted, and POMC, NPY, and AgRP mRNA abun-Figure 5. Deletion of SH2-B attenuates leptin-induced inhibition of food intake
and weight gain
Mice (7 weeks; wt: n = 4; KO: n = 4) were housed individually and injected
intraperitoneally with leptin (2 mg/kg body weight) or PBS (as control) twice a
day (6:00 p.m. and 12:00 a.m.) for 2 days (indicated by two arrows). Food intake
and body weight were monitored both before and after the injection. Changes in
food intake and body weight were calculated as a percentage of the initial values
prior to the injection.CELL METABOLISM : AUGUST 2005dance was measured by quantitative real-time PCR assays and
normalized to hypothalamic β-actin mRNA abundance. Hypo-
thalamic NPY and AgRP mRNA was elevated by 2 and 2.4
times, respectively, in SH2-B−/− males (Figure 6). The expres-
sion of orexigenic NPY and AgRP was also significantly in-
creased in SH2-B−/− females (Figure 6). In contrast, the levels
of anorexigenic POMC were similar between SH2-B−/− and
wild-type littermates (Figure 6). Because plasma leptin levels
were dramatically elevated in SH2-B−/− mice, hypothalamic
POMC neurons may also be leptin resistant, but to a lesser
extent than hypothalamic NPY/AgRP neurons in SH2-B−/−
mice. These data suggest that deletion of SH2-B may severely
impair leptin sensitivity in hypothalamic NPY/AgRP neurons,
resulting in a significant increase in the expression of NPY and
AgRP. The elevation of hypothalamic NPY and/or AgRP may
contribute to hyperphagia and obesity in SH2-B−/− mice.
The expression of hypothalamic LEPRb and SOCS3 was
similar between SH2-B−/− mice and wild-type littermates (data
not shown), suggesting that leptin resistance and obesity may
not be caused by an altered expression of these two proteins
in SH2-B−/− mice.
Disruption of the SH2-B gene impairs leptin signaling
in the hypothalamus
Since overexpressed SH2-B binds to and activates JAK2 in
cultured cells, SH2-B may increase leptin sensitivity by en-
hancing leptin-stimulated JAK2 activation in the hypothalamus.
To determine whether SH2-B is expressed in leptin target tis-
sues, hypothalami were isolated from SH2-B−/− mice and wild-
type littermates at 6 weeks of age and homogenized in lysis
buffer. Hypothalamic SH2-B was immunoprecipitated with
αSH2-B and immunoblotted with αSH2-B. Two forms of SH2-B
were detected in the hypothalamus (Figure 7A). Treatment with
alkaline phosphatase failed to alter the migration of these two
forms, suggesting that they represent two distinct isoforms of
SH2-B rather than differential phosphorylation states (data notFigure 6. Disruption of the SH2-B gene increases the expression of hypothalamic
NPY and AgRP
Males (12–14 weeks; wt: n = 7; KO: n = 7) or females (16 weeks; wt: n=6; KO:
n=13) were fasted for 8 hr (from 9:00 a.m. through 5:00 p.m.) and sacrificed by
decapitation. Total hypothalamic RNA was prepared, and NPY, AgRP, POMC,
and β-actin mRNA were measured using quantitative real-time PCR analysis. The
expression of NPY, AgRP, and POMC was normalized to the expression of
β-actin. *p < 0.05.99
A R T I C L EFigure 7. Disruption of the SH2-B gene attenuates leptin-stimulated JAK2 activation and tyrosine phosphorylation of STAT3 and IRS2
A) Hypothalamic extracts were prepared from wild-type and SH2-B−/− males (6 weeks), immunoprecipitated with αSH2-B, and immunoblotted with αSH2-B.
B) JAK2 in the ARC extracts was immunoprecipitated with αJAK2 and subjected to an in vitro kinase assay (top panel). The JAK2 protein levels were estimated by
immunoblotting with αJAK2 (bottom panel). Each lane represents hypothalamic JAK2 from two mice (7 weeks).
C) Hypothalamic extracts were prepared from leptin- (wt: n = 8; KO: n = 8) or PBS-treated mice (wt: n = 5; KO: n = 5) and immunoblotted with αphospho-STAT3.
STAT3 phosphorylation was normalized to total hypothalamic STAT3 protein.
D) Hypothalamic extracts were prepared from leptin- (wt: n = 8; KO: n = 8) or PBS-treated mice (wt: n = 5; KO: n = 5), immunoprecipitated with αIRS2, and
immunoblotted with anti-phospho-tyrosine. IRS2 phosphorylation was normalized to total hypothalamic IRS2 protein.
E) STAT3 was transiently coexpressed in HEK293LEPRb cells with PTP1B and Myc-tagged SH2-Bβ as indicated. Cells were treated with leptin (100 ng/ml) for various
times, and cell extracts were immunoblotted with αphospho-STAT3, αSTAT3, αPTP1B, or αMyc as indicated. *p < 0.05; **p < 0.01.shown). SH2-B mRNA produces at least four isoforms (α, β, γ,
and δ) via alternative splicing (Nelms et al., 1999; Yousaf et
al., 2001).
To determine whether SH2-B enhances leptin-stimulated
JAK2 activation in the hypothalamus, JAK2 tyrosine kinase ac-
tivity was measured in SH2-B−/− mice and wild-type littermates
at 7–8 weeks of age. Mice were fasted for 24 hr and injected
intraperitoneally with leptin (1 mg/kg body weight) or PBS, and
the ARC of the hypothalamus was isolated 30 min after injec-
tion. JAK2 was immunoprecipitated with αJAK2 and subjected
to an in vitro kinase assay in the presence of [γ-32P]-ATP. Leptin
stimulated JAK2 activation in the ARC in wild-type mice as ex-
pected, whereas leptin-stimulated JAK2 activation was signifi-
cantly reduced in SH2-B−/− male mice (Figure 7B).
To determine whether deletion of SH2-B impairs JAK2-medi-
ated pathways in the hypothalamus, leptin-stimulated tyrosine
phosphorylation of STAT3 and IRS2 was measured in SH2-B−/−
mice and wild-type littermates. JAK2 phosphorylates STAT3 at
Tyr705 in response to leptin, which is required for STAT3 activa-100tion. Fasted mice were injected intraperitoneally with leptin or
PBS, and hypothalamic extracts were prepared and immu-
noblotted with an anti-phospho-STAT3 (pTyr705) antibody. Lep-
tin stimulated STAT3 phosphorylation in wild-type mice as ex-
pected. In contrast, leptin-stimulated STAT3 phosphorylation
was significantly reduced in SH2-B−/− mice (Figure 7C).
To examine leptin-stimulated tyrosine phosphoryation of
IRS2, fasted mice were injected intraperitoneally with leptin or
PBS, and the hypothalamus was isolated. Two hypothalami
were pooled and homogenized in lysis buffer. IRS2 was immu-
noprecipitated with αIRS2 and immunoblotted with αPY. Leptin
stimulated tyrosine phosphorylation of IRS2 in wild-type mice;
in contrast, leptin failed to stimulate IRS2 phosphorylation in
SH2-B−/− mice (Figure 7D). Together, these results demonstrate
that deletion of SH2-B impairs leptin signaling in the hypothala-
mus, which may contribute to leptin resistance and obesity in
SH2-B−/− mice.
Leptin signaling is negatively regulated by PTP1B, a protein
tyrosine phosphatase that binds to and dephosphorylatesCELL METABOLISM : AUGUST 2005
SH2-B regulation of body weightJAK2 (Kaszubska et al., 2002; Myers et al., 2001). Genetic de-
letion of the PTP1B gene improves leptin sensitivity and pro-
tects against high-fat-diet-induced obesity (Cheng et al., 2002;
Zabolotny et al., 2002). To determine whether SH2-B counter-
acts PTP1B-mediated inhibition of leptin signaling, SH2-B and
PTP1B were transiently coexpressed in HEK293LEPRb cells that
stably express the leptin receptor LEPRb (Duan et al., 2004a).
Leptin-stimulated activation of STAT3 was examined by immu-
noblotting cell extracts with anti-phospho-STAT3 (pTyr705) anti-
body. Leptin stimulated STAT3 phosphorylation, which was in-
hibited by PTP1B as expected (Figure 7E). SH2-B rescued the
inhibition of STAT3 phosphorylation induced by PTP1B (Figure
7E). These results demonstrate that SH2-B is able to enhance
leptin signaling by counteracting the inhibitory effects of nega-
tive regulators, including PTP1B.
Discussion
SH2-B is widely expressed in multiple tissues, including the
brain, skeletal muscle, adipose tissue, and the liver, suggesting
that this molecule may have pleiotropic function in animals.
Consistent with this idea, SH2-B binds via its SH2 domain to
both the cytoplasmic tyrosine kinase JAK2 and multiple recep-
tor tyrosine kinases, mediating cell signaling in response to
multiple hormones, growth factors, and cytokines in cultured
cells. In animals, SH2-B is required for reproduction, presuma-
bly by mediating insulin-like growth factor I action in gonadal tis-
sues (Ohtsuka et al., 2002). We reported recently that SH2-B is
required for insulin regulation of glucose homeostasis in mice
(Duan et al., 2004b). In the current work, we demonstrated that
SH2-B is required for energy homeostasis. Genetic deletion of
the SH2-B gene resulted in hyperphagia and obesity. SH2-B
homozygous null mice developed a metabolic syndrome (hy-
perlipidemia, hyperglycemia, hyperleptinemia and hyperinsuli-
nemia, and hepatic steatosis), which is commonly associated
with obesity.
SH2-B enhances leptin-stimulated activation of the PI
3-kinase pathway by recruiting IRS proteins to JAK2 in cultured
cells (Duan et al., 2004a). In addition, overexpression of
SH2-B potentiates JAK2 activation (Rui and Carter-Su, 1999).
Consistent with these observations, we found that deletion of
SH2-B impaired leptin-stimulated JAK2 activation and tyrosine
phosphorylation of both STAT3 and IRS2 in the hypothalamus.
Since both the STAT3 and the IRS2/PI 3-kinase pathways are
required for leptin regulation of feeding and body weight, atten-
uation of the STAT3 and/or IRS2/PI 3-kinase pathways may
contribute to reduced ability of leptin to inhibit food intake and
weight gain in SH2-B−/− mice. Interestingly, overexpression of
SH2-B counteracted PTP1B-mediated inhibition of leptin sig-
naling, raising a possibility that leptin sensitivity may be modu-
lated by a balance between positive (e.g., SH2-B) and negative
regulators (e.g., SOCS3, PTP1B) in the hypothalamus. SH2-B-
deficient mice developed severe leptin resistance, and hyper-
leptinemia preceded the onset of obesity, suggesting that lep-
tin resistance may contribute to hyperphagia and obesity in
SH2-B−/− mice.
Leptin resistance is associated with increased energy intake
and reduced energy expenditure in most animal models of
obesity. Surprisingly, deletion of SH2-B increased both energy
intake and energy expenditure; however, energy intake still ex-
ceeded energy expenditure, resulting in obesity. One possibleCELL METABOLISM : AUGUST 2005explanation is that SH2-B expression and/or its ability to en-
hance leptin signaling may be different between neurons con-
trolling energy intake and neurons controlling energy expendi-
ture. Deletion of SH2-B may severely impair leptin signaling in
neurons regulating energy intake, resulting in hyperphagia. In
contrast, SH2-B deficiency may only mildly impair leptin sensi-
tivity in neurons regulating energy expenditure. Severe hyper-
leptinemia may overcome mild leptin resistance in these neu-
rons, resulting in elevated energy expenditure in SH2-B−/−
mice. Consistent with this idea, deletion of SH2-B severely im-
paired leptin sensitivity in the NPY/AgRP neurons in the hypo-
thalamus, resulting in a significant increase in the expression
of orexigenic NPY and AgRP, even in the presence of severe
hyperleptinemia. In contrast, the expression of anorexigenic
POMC was similarly between SH2-B−/− and wild-type litter-
mates. Since SH2-B is involved in cell signaling in response
to multiple hormones, growth factors, and cytokines, SH2-B
deficiency may additionally alter physiological actions of some
of these ligands, which may also contribute to energy imbal-
ance and obesity in SH2-B−/− mice.
SH2-B−/− mice developed hyperinsulinemia, hyperglycemia,
and glucose intolerance. SH2-B directly binds to the insulin
receptor, enhancing insulin-stimulated activation of the insulin
receptor and downstream pathways (Ahmed and Pillay, 2003;
Duan et al., 2004b; Kotani et al., 1998; Riedel et al., 1997;
Wang and Riedel, 1998). Deletion of SH2-B may directly impair
insulin sensitivity in the liver, skeletal muscle, and/or adipose
tissue, contributing to insulin resistance (Duan et al., 2004b).
Obesity may further exacerbate insulin resistance, resulting in
type 2 diabetes in SH2-B−/− mice.
Ohtsuka et al. reported that SH2-B−/− mice have growth re-
tardation and reduced body weight at 2–6 weeks of age, then
grow faster than wild-type mice and have similar body weights
as wild-type mice at 10 weeks of age (Ohtsuka et al., 2002).
We also observed growth retardation in young SH2-B−/− mice;
however, we demonstrated that SH2-B−/− mice progressively
develop obesity after 7 weeks of age. The expression of AgRP
was significantly increased in SH2-B−/− mice, which may inhibit
the melanocortin system in the hypothalamus. Inhibition of the
melanocortin system increases the sensitivity to stress and
stress-induced weight loss and reduction of food intake (De
Souza et al., 2000; Harris et al., 2001; Vergoni et al., 1999).
SH2-B−/− mice may be more sensitive to environmental stress,
potentially perturbing their energy homeostasis. The difference
in diets and environmental stress may explain the discrepancy
between our results and the observations reported by Ohtsuka
and coworkers.
In summary, we demonstrate that disruption of the SH2-B
gene resulted in severe leptin resistance, hyperphagia, obesity,
and obesity-associated metabolic syndrome. Leptin signaling
was significantly impaired in the hypothalamus in SH2-B−/−
mice. Moreover, SH2-B directly counteracted PTP1B-induced
inhibition of leptin signaling in cultured cells. These observa-
tions raise a possibility that SH2-B and SH2-B-regulated sig-
naling events may serve as potential therapeutic targets for a
treatment of obesity and type 2 diabetes.
Experimental procedures
Animal experiments
SH2-B knockout mice (in 129Sv/C57BL/6 genetic background) were gener-
ated by homologous recombination as described previously (Duan et al.,101
A R T I C L E2004b). SH2-B+/− males were backcrossed with wild-type C57BL/6 females
(Jackson Laboratory, Bar Harbor, Maine) for seven generations to obtain
SH2-B knockout mice in a C57BL/6 background. Mice were housed on a
12 hr/12 hr light/dark cycle in the Unit for Laboratory Animal Medicine
(ULAM) at the University of Michigan, with free access to water and stan-
dard mouse chow (9% fat content). Animal experiments were conducted
following the protocols approved by the University Committee on the Use
and Care of Animals (UCUCA).
Blood samples were collected from the tail vein and assayed for plasma
insulin and leptin using rat insulin or mouse leptin ELISA kits (Crystal Chem
Inc., Chicago, Illinois), respectively. Free fatty acids and TG were measured
using Wako NEFAC (Wako Chemicals USA, Inc., Richmond, Virginia) and
Free Glycerol Reagent (Sigma, St. Louis, Missouri), respectively.
For histological analysis, liver or adipose tissues were isolated and fixed
in Bouins solution (Sigma, St. Louis, Missouri). Paraffin sections were pre-
pared and stained with hematoxylin and eosin. Images were visualized
using BX51 Microscope (Olympus, Tokyo, Japan), and captured using a
DP70 microscope digital camera (Olympus, Tokyo, Japan).
To examine leptin inhibition of food intake and weight gain, SH2-B−/−
mice and wild-type littermates were housed individually with free access to
food and water. Mice were injected with leptin (2 mg/kg body weight) or
PBS (as control) twice daily (6:00 p.m. and 12:00 a.m.) for 2 days. Food
intake and body weight were monitored both before and after leptin in-
jection.
To measure tissue TG, tissue was homogenized in chloroform:methanol
(2:1) and incubated at room temperature for 4 hr. Tissue extracts were air
dried, resuspended in KOH (3 M), incubated at 70°C for 1 hr, neutralized
with MgCl2, and subjected to a TG assay as described above. To measure
total-body TG, animals were sacrificed, and the gastrointestinal track and
head were removed. Carcasses were incubated in alcoholic KOH at room
temperature for 4 weeks. The extracts were neutralized with MgCl2 and
subjected to a TG assay.
Measurements of energy expenditure
Metabolic rates were measured by indirect calorimetry (Windows Oxymax
Equal Flow System, Columbus Instruments, Columbus, Ohio) in 17- to 19-
week-old mice. Mice were housed individually in air-tight respiratory cages
through which room air was passed at a flow rate of 0.5 liters/min. Exhaust
air was sampled at 27 min intervals for a period of 1 min; O2 and CO2
content of the exhaust was determined by comparison to O2 and CO2
content of standardized sample air. Mice were acclimatized to the cages
for 48 hr before measurements. Lean body mass and fat content were de-
termined using a dual-energy X-ray absorptiometry method (Dexa, Sabre
Bone Densitormetry, Norland Med). VO2, VCO2, and heat production were
normalized to lean body mass.
Quantitative real-time PCR analysis
Mice were fasted for 8 hr (from 9:00 a.m. through 5:00 p.m.) and sacrificed
by decapitation. The hypothalamus was isolated immediately, and total hy-
pothalamic RNA was prepared using TRIzol reagent (Invitrogen Life Tech-
nologies, Carlsbad, California). The first-strand cDNAs were synthesized
using oligo dT (12–18) and M-MLV reverse transcriptase (Promega, Madi-
son, Wisconsin). NPY, POMC, AgRP, and β-actin mRNAs were measured
using the Brilliant SYBR Green QPCR kit and Mx3000P real-time PCR sys-
tem (Stratagene, La Jolla, California). The expression of NPY, AgRP, and
POMC was normalized to the expression of β-actin. Primers for real time
RT-PCR were the following: NPY sense 5#-TCAGACCTCTTAATGAAGG
AAAGCA-3#, NPY antisense 5#-GAGAACAAGTTTCATTTCCCATCA-3#; AgRP
sense 5#- GGCCTCAAGAAGACAACTGC, AgRP antisense 5#- GACTCGT
GCAGCCTTACACA-3#; POMC sense 5#-CTGCTTCAGACCTCCATAGAT
GTG-3, POMC antisense CAGCGAGAGGTCGAGTTTGC; β-actin sense 5#-
AAATCGTGCGTGACATCAAA-3#, β-actin antisense 5#- AAGGAAGGCTGG
AAAAGAGC.
JAK2 in vitro kinase assay
SH2-B−/− mice and wild-type littermates (7 weeks) were fasted for 24 hr
and injected intraperitoneally with leptin (1 mg/kg body weight) or PBS (as
control). Thirty minutes later, the brain was removed and placed in a cooled
mouse brain matrix with 1 mm section dividers (ASI Instruments Inc., War-
ren, Michigan). The brain was cut sagittally to separate the two hemi-102spheres. Two additional sagittal cuts produced two 1 mm thick sagittal sec-
tions to the left and right of the third ventricle. Landmarks (the fornix, optic
tracts, and mammillary nuclei) were used to dissect ARC enriched tissues.
The two tissue pieces from each brain region were combined. ARC was
combined from two mice treated identically, and homogenized in lysis buffer
(50 mM Tris-HCl [pH 7.5], 5 mM EDTA, 10 mM Na4P2O7, 100 mM NaF, 250
mM sucrose, 1% NP40). JAK2 was immunoprecipitated with αJAK2 and
washed with kinase buffer (50 mM HEPES [pH 7.6], 10 mM MnCl2, 0.5 mM
DTT, 100 mM NaCl, 1 mM Na3VO4). Immunopurified JAK2 was incubated
in the kinase buffer containing 20 uM cold ATP, 300 uCi [γ-32P]-ATP/ml;
resolved by SDS-PAGE; and visualized by autoradiography as we described
previously (Rui and Carter-Su, 1999).
Immunoprecipitation and immunoblotting
SH2-B−/− mice and wild-type littermates (7 weeks) were fasted for 24 hr
and injected intraperitoneally with leptin (1 mg/kg body weight) or PBS (as
control). Forty-five minutes later, mice were sacrificed by decapitation, and
the hypothalamus was isolated and homogenized in lysis buffer as de-
scribed above. The same amount of protein in hypothalamic extracts were
immunoblotted with anti-phospho-STAT3 (pTyr705) antibody (Santa Cruz,
California). The same blots were reprobed with anti-STAT3 antibody (Santa
Cruz, California) to estimate total STAT3 protein. In parallel experiments,
hypothalamic extracts were immunoprecipitated with αIRS2 and immu-
noblotted with anti-phosphotyrosine antibody (PY20) (Upstate Biotechnol-
ogy Inc., Lake Placid, New York). The same blots were reprobed with αIRS2
to estimate total IRS2 protein.
Transfection
HEK293LEPRb cells were split at 2 × 105 cells per well in 6-well culture dishes
24 hr before transfection and transfected with indicated plasmids using Li-
pofectamine 2000 reagents according to the manufacturer’s instruction.
Cells were deprived of serum overnight 24 hr after transfection and then
treated with 100 ng/ml mouse leptin for the indicated time. Cell extracts
were prepared and subjected to immunoblotting with indicated antibody.
Statistical analysis
The data are presented as the mean ± SEM. Student’s t tests were used
for comparisons beteween two groups. P < 0.05 was considered statistic-
ally significant.
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